Clear All
731 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
NA Selpercatinib Retevmo 40mg, 80mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2020 In Use
Vimseltinib Romvimza 14mg, 20mg, 30mg Chemotherapy Tyrosine Kinase Inhibitor CSF1R Yes 2025 In Use
NA Trifluridine and Tipiracil Lonsurf 15/6.14 mg Chemotherapy Antimetabolite Pyrimidine Analog Yes 2015 In Use
NA Dabrafenib Tafinlar 50 mg Chemotherapy Tyrosine Kinase Inhibitor BRAF Yes 2013 Jan 1, 2004 In Use
NA Palbociclib Ibrance 100 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
C9448 Netupitant/Palonosetron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 Apr 1, 2015 Jun 30, 2015 No Longer Used
NA Palbociclib Ibrance 75 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
Revumenib Revuforj 25mg, 110mg, 160mg Chemotherapy Enzyme Inhibitor KMT2A Yes 2024 In Use
NA Rucaparib Rubraca 300 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
Nirogacestat Ogsiveo 50mg, 100mg, 150mg Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Yes 2023 In Use
NA Chlorotrianisene Anisene 12 mg Hormonal Therapy Estrogen Yes 1992 1997 In Use
NA Ripretinib Qinlock 50mg Chemotherapy Tyrosine Kinase Inhibitor KIT, PDGFRA Yes 2020 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Tivozanib Fotivda 0.89mg, 1.34mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2021 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
Q0180 Dolasetron Mesylate Anzemet 100 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1997 Apr 1, 1998 In Use
NA Estradiol Estrace 0.5mg Hormonal Therapy Estrogen Yes 1998 In Use
NA Cyclosporine NeOral 25mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 1995 In Use
NA Dasatinib Sprycel 70 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Elacestrant Orserdu Multiple Hormonal Therapy Estrogen Receptor Antagonist ERɑ Yes 2023 In Use
NA Dasatinib Sprycel 20 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Thalidomide Thalomid 150 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Quizartinib Vanflyta Multiple Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2023 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.